Engram v.GSK Consumer Healthcare Holdings(US)Inc.

CourtDistrict Court, E.D. New York
DecidedSeptember 30, 2021
Docket1:19-cv-02886
StatusUnknown

This text of Engram v.GSK Consumer Healthcare Holdings(US)Inc. (Engram v.GSK Consumer Healthcare Holdings(US)Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Engram v.GSK Consumer Healthcare Holdings(US)Inc., (E.D.N.Y. 2021).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK ------------------------------------x

CLINTON ENGRAM,

Plaintiff, MEMORANDUM & ORDER 19-CV-2886(EK)(PK)

-against-

GSK CONSUMER HEALTHCARE HOLDINGS(US)INC.,

Defendant.

------------------------------------x ERIC KOMITEE, United States District Judge: Defendant GSK Consumer Health Holdings markets a lip balm sold under the Chapstick brand name called “2 in 1 Lipcare.” The name is a reference to the single product’s two functions: moisturizing and sun protection. Plaintiff Clinton Engram alleges that the product’s labeling is misleading as to the length of sun protection it provides, and that the label therefore constitutes a “deceptive act or practice” and “false advertising” under New York’s General Business Law Sections 349 and 350. Plaintiff also alleges unjust enrichment and indicates his intent to seek class certification. Defendant moves to dismiss under Rule 12(b)(6) for failure to state a claim. I grant Defendant’s motion in its entirety, as I conclude that the reasonable consumer would not be misled by the representations at issue. I. Background The Chapstick product at issue is, like many lip balms, sold in a hard plastic tube. Plaintiff’s original complaint alleged that the tube was sold in clear plastic packaging that the parties refer to as a “blister pack.” That

outside packaging provided additional space for marketing text and federally mandated drug facts. The original complaint, filed in May 2019 (“Original Complaint”), ECF No. 1, included three photographs: one showing the front of the plastic packaging; one showing the back of that packaging; and one of the tube itself (just the front side). These photographs are reproduced below. As the photographs depict, the front of the package and the front of the tube both contain a circle, bisected horizontally. In the top half of the circle is the phrase “8 HOUR MOISTURE,” written in white letters against a blue background. In the bottom half, in blue letters on a white and

gray background, is the phrase “SPF 15.” OTP Tee

eres 6°) eto... 1s spF15 PROTECTION (iY lol RU]5 F412 Bote oe ; == ae a oc

Plaintiff does not contest the accuracy of either of these claims — that the product moisturizes for eight hours, or that it contains a sun-protection factor of 15. Instead, he claims that the proximity of these claims to one another would lead the reasonable consumer to conflate them, and as a consequence to misunderstand that the product provides eight hours of sun protection. Indeed, Plaintiff alleges that he personally “relied upon” the product’s “representations to belief [sic] that the product he bought would provide 8 hours of SPF 15 protection.” First Amended Complaint (“the FAC”) @ 19, ECF No. 29. According to Plaintiff, the Defendant’s “misrepresentation” — the suggestion that the product contains “8 hour sun protection” — “increases the risk of consumer harm, because it encourages less-frequent and under-application” of the product. Id. 77 6, 8. Additionally, Plaintiff alleges,

consumers paid a premium for longer protection than the product delivers. Id. 7 11. The back of the packaging sets out “Directions” for using the product. As shown in the photograph below, the user is directed to “apply liberally 15 minutes before sun exposure”; “reapply at least every 2 hours”; and “use a water resistant sunscreen if swimming or sweating.” Original Complaint 7 4. Marketed by: Pfizer, Madison, NJ 07940 USA © 2018 Pfizer inc. For most recent product information, visit oO vevew.chapstick.com My PAAOS8547 in

OTT Yea oO Drug Facts he Active ingredients Purposes Ayobenzone 3% Octinovate 7.5% o.oo. SUNSCTABNS White petrolatum 42.3%6......... Skin protectant {Paraben Free Uses mbelps prevent sunbum mifusedas | Drug Facts (continued) directed with other sun protection measures (see | Sun Protection Measures. Spending arenas foe ir a a time in the sun increases your risk of skin cancer and early skin aging. To decrease prevent and temporarily protects chafed, chapped | this risk, saat use witha or cracked lips mihelps prevent and protect =] Broad Spectrum SPF value of 15 or higher from the drying effects of wind and cold weather § and other sun protection measures including: ; Wm limited time in the sun, especially from — use only 10am.-—2p.m. Miwear long-sleeved Do not use on damaged or broken skin ain = i □ ao Se ar) mes When using this product keep aut of eyes. oe Rinse with water to remove. product from excessive heat and direct sun Keep out of reach of children. if swallowed, get | Inactive ingredients aloe harbadensis medical help or contact a Poison Control Center leaf extract, camauba wax, cetyl alcohol, Tight away. fragrance, isocety stearate, isopropyl lanolate, : lanolin, mineral oil, paraffin, saccharin, Directions w apply liberally 15 minutes tocophery/ linoleate/oleate, vitamin E acetate, before sun exposure mireapply atleast every ft white wax 2hours miuse a water resistant sunscreen if swimming or sweating mi children under 6 Questions or comments? call weekdays months of age: Ask a doctor D | trom to5 PM EST at 1-877-227-3421

At oral argument on Defendant’s motion to dismiss the original complaint, the parties and the Court engaged in extended colloquy about the extent to which the “Directions” on

the reverse of the package — specifically the directive to “reapply at least every two hours” — could serve to minimize any alleged confusion emanating from the front of the package. Following oral argument, the Court granted Plaintiff’s motion to amend the complaint. The FAC, submitted thereafter, simply

deleted the images of the blister packaging, including the image of the reverse of the package and any reference thereto. Thus, the FAC — now the operative complaint — displays only the single photo of the front of the tube.1 The FAC also added an allegation that “a survey conducted in May of 2020” — i.e., after oral argument — “by a neutral third party of 402 consumers” showed that “259 of them (64.4%) believed that the Product provided 8 hours of sun protection based on the packaging.” FAC ¶ 5. Plaintiff attached the survey (which was titled “Report for Project — 031520-1 ChapStick Study”) to a letter filed with the Court on May 22,

2020. Pl.’s Ltr. dated May 22, 2020, ECF No. 27. The filings do not indicate who conducted the survey (apart from calling them “neutral”). The survey indicates, on its face, that the respondents were shown a picture of the front of the Chapstick tube, but not the full package — including the reverse of the

1 For reasons discussed in Part II below, I consider all three images of the package in question, despite the deletion. See, e.g., Pichardo v. Only What You Need, Inc., No. 20-CV-493, 2020 WL 6323775, at *3 n.5 (S.D.N.Y. Oct. 27, 2020). package, where the direction to “reapply at least every 2 hours” appears. See id. Ex. A, ECF No. 27-1 (survey attachment). II. Discussion On a motion to dismiss under Fed. R. Civ. P. 12(b)(6), “the court’s task is to assess the legal feasibility of the

complaint.” Lynch v. City of New York, 952 F.3d 67, 75 (2d Cir. 2020). In doing so, the Court “must take the facts alleged in the complaint as true, drawing all reasonable inferences in [the plaintiff’s] favor.” In re NYSE Specialists Sec. Litig., 503 F.3d 89, 91 (2d Cir. 2007). To survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to “state a claim to relief that is plausible on its face.” Ashcroft v. Iqbal,

Related

In Re NYSE Specialists Securities Litigation
503 F.3d 89 (Second Circuit, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Fink v. Time Warner Cable
714 F.3d 739 (Second Circuit, 2013)
Williams v. Gerber Products Co.
552 F.3d 934 (Ninth Circuit, 2008)
Violette v. Armonk Associates, L.P.
872 F. Supp. 1279 (S.D. New York, 1995)
Gristede's Foods, Inc. v. Unkechauge Nation
532 F. Supp. 2d 439 (E.D. New York, 2007)
Kwan v. The Andalex Group LLC
737 F.3d 834 (Second Circuit, 2013)
Orlander v. Staples, Inc.
802 F.3d 289 (Second Circuit, 2015)
Kommer v. Bayer Consumer Health
710 F. App'x 43 (Second Circuit, 2018)
Lynch v. City of New York
952 F.3d 67 (Second Circuit, 2020)
Dash v. Seagate Technology (U.S.) Holdings, Inc.
27 F. Supp. 3d 357 (E.D. New York, 2014)
Nelson v. MillerCoors, LLC
246 F. Supp. 3d 666 (E.D. New York, 2017)
Kommer v. Bayer Consumer Health
252 F. Supp. 3d 304 (S.D. New York, 2017)
Davis v. Hain Celestial Grp., Inc.
297 F. Supp. 3d 327 (E.D. New York, 2018)
Mantikas ex rel. Situated v. Kellogg Co.
910 F.3d 633 (Second Circuit, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
Engram v.GSK Consumer Healthcare Holdings(US)Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/engram-vgsk-consumer-healthcare-holdingsusinc-nyed-2021.